Access Bio

Executive Summary

Access Bio, founded in 1999 and headquartered in Somerset, New Jersey, is a private in vitro diagnostics company dedicated to combating malaria and other serious diseases through high-quality diagnostic products. The company has successfully commercialized tests for malaria and aims to expand its portfolio to address additional infectious diseases, leveraging its expertise in rapid diagnostic tests (RDTs) and point-of-care solutions. With a focus on underserved markets, particularly in malaria-endemic regions, Access Bio benefits from growing global demand for affordable and reliable diagnostics, driven by initiatives from the WHO and other health organizations. The company's long operating history and niche specialization position it for steady growth, though its private status limits visibility into financials and pipeline. Key opportunities include expanding into new disease areas and securing regulatory approvals for enhanced product lines.

Upcoming Catalysts (preview)

• Q4 2026WHO prequalification of a new malaria RDT70% success
• Q2 2027Strategic partnership for distribution in Africa60% success
• Q1 2027Extension of product line to dengue or Zika diagnostics50% success